130 related articles for article (PubMed ID: 17257070)
21. Increased proliferation, cytotoxicity, and gene expression after stimulation of human peripheral blood T lymphocytes through a surface ganglioside (GD3).
Norihisa Y; McVicar DW; Ghosh P; Houghton AN; Longo DL; Creekmore SP; Blake T; Ortaldo JR; Young HA
J Immunol; 1994 Jan; 152(2):485-95. PubMed ID: 8283032
[TBL] [Abstract][Full Text] [Related]
22. Interleukin-2 enhancement of monoclonal antibody-mediated cellular cytotoxicity against human melanoma.
Munn DH; Cheung NK
Cancer Res; 1987 Dec; 47(24 Pt 1):6600-5. PubMed ID: 3499978
[TBL] [Abstract][Full Text] [Related]
23. Defucosylated anti-CCR4 monoclonal antibody exerts potent ADCC against primary ATLL cells mediated by autologous human immune cells in NOD/Shi-scid, IL-2R gamma(null) mice in vivo.
Ito A; Ishida T; Utsunomiya A; Sato F; Mori F; Yano H; Inagaki A; Suzuki S; Takino H; Ri M; Kusumoto S; Komatsu H; Iida S; Inagaki H; Ueda R
J Immunol; 2009 Oct; 183(7):4782-91. PubMed ID: 19748990
[TBL] [Abstract][Full Text] [Related]
24. Synergetic effect of interleukin-2 and cellular cytotoxicity against a novel tumor-associated carbohydrate antigen Le(a)/Le(a) (dimeric Le(a)) mediated by monoclonal antibody NCC-ST-421 in adoptive immunization using SCID mice.
Watanabe M; Kubota T; Kitajima M; Hakomori S
Cancer Immunol Immunother; 1993 Sep; 37(4):245-50. PubMed ID: 8348564
[TBL] [Abstract][Full Text] [Related]
25. The activation of natural killer cell effector functions by cetuximab-coated, epidermal growth factor receptor positive tumor cells is enhanced by cytokines.
Roda JM; Joshi T; Butchar JP; McAlees JW; Lehman A; Tridandapani S; Carson WE
Clin Cancer Res; 2007 Nov; 13(21):6419-28. PubMed ID: 17962339
[TBL] [Abstract][Full Text] [Related]
26. Interleukin-2 enhancement of cytotoxicity by humanized monoclonal antibody M195 (anti-CD33) in myelogenous leukemia.
Caron PC; Lai LT; Scheinberg DA
Clin Cancer Res; 1995 Jan; 1(1):63-70. PubMed ID: 9815888
[TBL] [Abstract][Full Text] [Related]
27. Mapping the functional topography of Fc gamma with monoclonal antibodies: localization of epitopes interacting with the binding sites of Fc receptor on human K cells.
Sármay G; Jefferis R; Klein E; Benczur M; Gergely J
Eur J Immunol; 1985 Oct; 15(10):1037-42. PubMed ID: 2414110
[TBL] [Abstract][Full Text] [Related]
28. Prestimulation of monocytes by the cytokines GM-CSF or IL-2 enhances the antibody dependent cellular cytotoxicity of monoclonal antibody 17-1A.
Flieger D; Spengler U; Beier I; Sauerbruch T; Schmidt-Wolf IG
Z Gastroenterol; 2000 Aug; 38(8):615-22. PubMed ID: 11031784
[TBL] [Abstract][Full Text] [Related]
29. Tumor growth suppression by a mouse/human chimeric anti-CEA antibody and lymphokine-activated killer cells in vitro and in SCID mouse xenograft model.
Senba T; Kuroki M; Arakawa F; Yamamoto T; Kuwahara M; Haruno M; Ikeda S; Matsuoka Y
Anticancer Res; 1998; 18(1A):17-24. PubMed ID: 9568050
[TBL] [Abstract][Full Text] [Related]
30. Combinations of the cytokines IL-12, IL-2 and IFN-alpha significantly augment whereas the cytokine IL-4 suppresses the cytokine-induced antibody-dependent cellular cytotoxicity of monoclonal antibodies 17-1A and BR55-2.
Flieger D; Spengler U; Beier I; Sauerbruch T; Schmidt-Wolf I
Cytokine; 2000 Jun; 12(6):756-61. PubMed ID: 10843759
[TBL] [Abstract][Full Text] [Related]
31. Murine monoclonal IgG3 to human colorectal tumor-associated antigens: enhancement of antibody-dependent cell-mediated cytotoxicity by interleukin 2.
Morgan AC; Sullivan W; Graves S; Woodhouse CS
Cancer Res; 1989 May; 49(10):2773-6. PubMed ID: 2785437
[TBL] [Abstract][Full Text] [Related]
32. Monoclonal antibodies against leucoagglutinin-reactive human T lymphocyte surface components. Two antibodies which inhibit cell-mediated cytotoxicity at a post-binding stage.
Vargas-Cortes M; Hammarström ML; Hammarström S; Hellström U; Perlmann P
Eur J Immunol; 1986 Jul; 16(7):795-801. PubMed ID: 3522246
[TBL] [Abstract][Full Text] [Related]
33. Antibody-dependent, cell-mediated cytotoxicity by an anti-class II murine monoclonal antibody: effects of recombinant interleukin 2 on human effector cell lysis of human B-cell tumors.
Biddle WC; Pancook J; Goldrosen M; Han T; Foon KA; Vaickus L
Cancer Res; 1990 May; 50(10):2991-6. PubMed ID: 2334902
[TBL] [Abstract][Full Text] [Related]
34. Lymphokine-activated killer cell cytotoxicity against human colon carcinomas enhanced by monoclonal antibody D612.
Pendurthi TK; Parker R; Schlom J; Primus FJ
Int J Cancer; 1990 Dec; 46(6):1021-8. PubMed ID: 2123477
[TBL] [Abstract][Full Text] [Related]
35. Virus-induced enhancement of lymphocyte-mediated antibody-dependent cytotoxicity (ADCC) in vitro.
Alsheikhly AR; Wåhlin B; Andersson T; Perlmann P
J Immunol; 1984 Jun; 132(6):2760-6. PubMed ID: 6373918
[TBL] [Abstract][Full Text] [Related]
36. Enhancement of antibody dependent cellular cytotoxicity (ADCC) by combination of cytokines.
Flieger D; Spengler U; Beier I; Kleinschmidt R; Hoff A; Varvenne M; Sauerbruch T; Schmidt-Wolf I
Hybridoma; 1999 Feb; 18(1):63-8. PubMed ID: 10211790
[TBL] [Abstract][Full Text] [Related]
37. Defucosylated humanized anti-CCR4 monoclonal antibody KW-0761 as a novel immunotherapeutic agent for adult T-cell leukemia/lymphoma.
Ishii T; Ishida T; Utsunomiya A; Inagaki A; Yano H; Komatsu H; Iida S; Imada K; Uchiyama T; Akinaga S; Shitara K; Ueda R
Clin Cancer Res; 2010 Mar; 16(5):1520-31. PubMed ID: 20160057
[TBL] [Abstract][Full Text] [Related]
38. Activation of cellular cytotoxicity and complement-mediated lysis of melanoma and neuroblastoma cells in vitro by murine antiganglioside antibodies MB 3.6 and 14.G2a.
Mayer P; Handgretinger R; Bruchelt G; Schaber B; Rassner G; Fierlbeck G
Melanoma Res; 1994 Apr; 4(2):101-6. PubMed ID: 8069095
[TBL] [Abstract][Full Text] [Related]
39. Stimulation of T lymphocyte proliferation by monoclonal antibodies against GD3 ganglioside.
Welte K; Miller G; Chapman PB; Yuasa H; Natoli E; Kunicka JE; Cordon-Cardo C; Buhrer C; Old LJ; Houghton AN
J Immunol; 1987 Sep; 139(6):1763-71. PubMed ID: 2887619
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of human antibody-dependent cellular cytotoxicity, cell-mediated cytotoxicity, and natural killing by a xenogeneic antiserum prepared against "activated" alloimmune human lymphocytes.
Neville ME; Hiserodt JC
J Immunol; 1982 Mar; 128(3):1246-51. PubMed ID: 6976989
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
